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Abstract:
In population-based studies, heart failure with normal left ventricular (LV) ejection fraction (HFNEF) is now increasingly recog-
nized and referred to as diastolic heart failure. However, the pathogenic mechanisms underlying HFNEF are incompletely under-
stood, mainly because of limited availability of human myocardial biopsy material. Nevertheless, recent studies have examined in
vivo hemodynamics, in vitro cardiomyocyte function, myofilamentary protein composition, collagen content and deposition of ad-
vanced glycation end products from LV endomyocardial biopsies. These measures were compared between HFNEF patients, sub-
jects without symptoms of heart failure (controls), patients with heart failure and reduced ejection function (HFREF), and patients
with HFNEF and HFREF with diabetes mellitus. This article summarizes the various findings of these studies and focuses on the
possible correlations among altered LV myocardial structure, cardiomyocyte function, myofilamentary proteins, and extracellular
matrices. These findings revealed novel mechanisms responsible for diastolic LV dysfunction, and they have important therapeutic
implications, particularly HFNEF, for which a specific heart failure treatment strategy is largely lacking.
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Abbreviations: AGEs – advanced glycation end products,
CVF – collagen volume fraction, ECM – extracellular matrix,
HFNEF – heart failure with normal ejection fraction, HFREF –
heart failure with reduced ejection fraction, LVEF – left ven-
tricular ejection fraction, PKA – protein kinase A
Introduction
Heart failure with normal ejection fraction (HFNEF)
is currently diagnosed in approximately half of heart
failure patients [11]. The majority of HFNEF patients
are elderly women with a history of systolic hyperten-
sion, many with left ventricular (LV) hypertrophy,
obesity, and diabetes [10, 23, 30, 33]. Despite the in-
creased recognition of LV diastolic dysfunction and
HFNEF, the pathophysiology of this disease remains
controversial. Furthermore, evidence-based guidelines
for management of HFNEF are largely lacking [21].
Many basic questions remain unanswered on the me-
chanisms underlying LV diastolic dysfunction. Im-
paired LV relaxation [22], decreased LV distensibility,
increased LV end-diastolic stiffness [3, 45, 46], and
pericardial and right ventricular constraint [32, 34]
have all been implicated as contributing factors to LV
Pharmacological Reports, 2009, 61, 139–145 139
Pharmacological Reports
2009, 61, 139–145
ISSN 1734-1140
Copyright © 2009
by Institute of Pharmacology
Polish Academy of Sciences
diastolic dysfunction. However, the most probable
scenario is that diastolic dysfunction integrates abnor-
malities of the extracellular matrix (ECM), cardio-
myocytes and their myofilamentary proteins [20]
(Fig. 1B–D). Nevertheless, the relative contribution of
these factors to diastolic indices of LV function in
vivo (Fig. 1A) is obscure. Failure to resolve these con-
troversies mainly arises from the difficulties in ob-
taining human biopsy and/or necropsy materials [20,
37], which would allow clinical and hemodynamic
features to be correlated with cellular and molecular
myocardial properties. The relative involvement of
the aforementioned elements was recently examined
in in vitro studies using LV endomyocardial biopsies
of HFNEF patients. This review summarizes the dif-
ferences in LV myocardial structure and function and
recapitulates the suggested novel mechanisms respon-
sible for the abnormal diastolic LV function.
Clinical characteristics and in vivo
hemodynamics
As proposed in the consensus statement by the Heart
Failure and Echocardiography Associations of the
European Society of Cardiology, the diagnosis of
HFNEF requires the following conditions to be satis-
fied: 1) signs or symptoms of heart failure; 2) normal
or mildly abnormal systolic LV function; 3) evidence
of diastolic LV dysfunction [35]. Normal or mildly
abnormal systolic LV function implies both a left ven-
tricular ejection fraction (LVEF) of greater than 50%
and an LV end-diastolic volume index (LVEDVI) of
less than 97 mL/m2. Diagnostic evidence of diastolic
LV dysfunction can be obtained invasively (LV end-
diastolic pressure (LVEDP) > 16 mmHg or mean pul-
monary capillary wedge pressure > 12 mmHg) or
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Fig. 1. Determinants of HFNEF. (A) LV diastolic pressure-volume relation in HFNEF is shifted upward when measured in vivo, indicating an in-
crease in LVEDP. (B) The altered diastolic properties are coupled with changes in the ECM that surrounds each myocyte. Collagen can also be
post-translationally cross-linked and alter properties of the ECM by protein-glucose interaction (generation of AGEs). (C) At the level of the car-
diomyocyte, calcium handling and signaling proteins are particularly important. Changes in the expression of the Na+/Ca2+ exchanger (NCX),
Ca2+ uptake proteins (PLB, SERCA), sarcoplasmic reticular Ca2+ channel (RyR) and ion pumps (e.g., Na+/K+ ATPase, NKATP) and their post-
translation modifications by several protein kinases (PKA, PKC, PKG) can alter their activity. (D) At the level of the myofilaments, alterations in
proteins within the thick and thin filaments, myosin-binding protein C (MyBPC), and the giant cytoskeletal protein titin can lead to abnormal car-
diomyocyte stiffness and relaxation
non-invasively by tissue Doppler (TD) (E/E’ > 15).
The transvascular catheter technique used in our re-
cent studies [6, 39, 40] allowed us to assess hemody-
namic characteristics in each individual patient at the
time of cardiac catheterization and biopsy sample re-
trieval. Invasive measurements combined with echo-
cardiography revealed a significantly higher LV peak
systolic pressure (LVPSP), LVEDP, circumferential
LV end-diastolic wall stress () and radial myocardial
stiffness modulus (SM) in the HFNEF patient group
compared to similar measures in the control group
[6]. The increased LVEDP and  with comparable
LVEDVI indicated a reduced LV diastolic distensibil-
ity, and the increased SM suggested increased myo-
cardial stiffness in the HFNEF patient group. By com-
paring clinical characteristics of HFNEF patients with
HFREF patients, we found that more HFNEF patients
had a history of arterial hypertension and were obese
[39]. LVPSP, LVEF, cardiac index, deceleration time
and SM were all higher in HFNEF patients. In addi-
tion, we found that diabetic HFNEF and HFREF pa-
tients had reduced LV diastolic distensibility and
a higher SM compared to non-diabetic patients [40].
Moreover, LVMI was higher in HFREF and HFNEF
patients compared to the control population. The ele-
vated LVMI in HFREF patients was believed to be
a compensatory mechanism to preserve LV wall thick-
ness with the larger LVEDVI. However, in HFNEF
patients, the elevated LVMI resulted in significant in-
creases in LV wall thickness and LVMI/LVEDVI ra-
tio. These findings indicated that eccentric LV hyper-
trophy occurs in HFREF, while HFNEF could be
characterized by concentric LV hypertrophy.
Level of ECM: fibrosis and advanced
glycation end (AGE) product deposition
Diastolic properties are frequently linked to character-
istics of the ECM that surrounds each myocyte and
forms bundles among muscle fibers. Connective tis-
sue consists of perimysial fibers enveloping groups of
myocytes, smaller endomysial fibers supporting and
connecting individual cells, and endomysial weaves
enveloping individual myocytes [20]. Many studies
have suggested the importance of myocardial fibrosis
in diastolic dysfunction [25, 27]. Moreover, recent
studies have begun to target signaling factors for fi-
brosis [13, 24, 31] and correlate changes in colla-
gen/fibrosis with chamber stiffening. A direct link be-
tween fibrosis and stiffness may seem to be well es-
tablished, yet controversy exists. Not all quantitative
assessments of fibrosis in larger animal models of heart
failure and in humans have identified correlations be-
tween stiffness and collagen content. In our recent
studies, histological analysis of human endomyocar-
dial biopsies revealed higher collagen volume frac-
tions (CVF) in HFNEF patients than in controls [6].
HFNEF patients were equally distributed over low, in-
termediate and high CVF classes. In low and interme-
diate CVF classes, the elevated indices of diastolic
function (LVEDP,  and SM), despite low levels of
interstitial fibrosis, indicated that CVF is not the sole
contributor to diastolic LV dysfunction.
Increased diastolic LV stiffness is recognized as the
earliest manifestation of LV dysfunction induced by
diabetes mellitus, and it frequently becomes the main
functional deficit of the diabetic heart [12, 15, 19].
However, as shown in our comparative histological
study, the mechanisms underlying the increased dia-
stolic LV stiffness differ between HFREF and HFNEF
patients. Deposition of AGEs and collagen were
found to be important determinants of the increased
LV stiffness in diabetic patients with HFREF, whereas
high cardiomyocyte resting tension (Fpassive) was
likely responsible for the increased LV stiffness in
diabetic patients with HFNEF [40]. Deposition of
AGEs with concomitant protein/glucose interaction
results from long-standing hyperglycemia and affects
diastolic LV stiffness through direct and indirect
mechanisms [1, 20, 36]. AGE cross-linking of colla-
gen increases its tensile strength, and this altered bio-
physical property of collagen increases diastolic LV
stiffness. In addition, AGE deposition can indirectly
augment diastolic LV stiffness through enhanced col-
lagen formation and reduced nitric oxide bioavailabil-
ity. Indeed, enhanced collagen formation in the pres-
ence of AGEs was confirmed in our recent study [40],
and low myocardial nitric oxide bioavailability was
previously demonstrated in HFREF patients [4, 5].
Postmyocarditis patients with HFREF frequently
show signs of persistent myocardial microvascular in-
flammation [38]. This inflammation may facilitate
AGE deposition [4] and may explain the preferential
AGE deposition in small intramyocardial vessels of
diabetic patients with HFREF. The clinical impor-
tance of endothelial AGE deposition was recently
confirmed in hypertensive patients who showed im-
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proved endothelial function with a cross-link breaker
[43]. We observed higher CVF values in diabetic than
in non-diabetic HFREF patients [40]. Activation of fi-
broblasts in diabetic HFREF patients may also result
from the aforementioned AGE deposition, protein ki-
nase C activation, cyclooxygenase-2 up-regulation, or
high intracellular glucose concentrations [1, 3, 8].
Cardiomyocyte level: structural and
functional alterations
Increased cardiomyocyte diameter and Z-line
thickness in HFNEF
Basic studies have provided histological evidence of
cardiomyocyte hypertrophy in HFNEF [39, 40]. The
increased myocyte diameter (MyD) in HFNEF and
the marginally increased MyD in HFREF resemble
the previously reported cardiomyocyte remodeling in
concentric and eccentric LV hypertrophy [16]. In con-
centric LV hypertrophy, cardiomyocytes grow in a trans-
verse direction while maintaining a constant cell
length, whereas in eccentric hypertrophy, cardiomyo-
cytes grow proportionally in longitudinal and trans-
verse directions. This difference in cardiomyocyte re-
modeling correlates with distinct patterns of peptide
growth factor induction in both conditions [9]. As
shown in our studies, different correlation exists be-
tween cardiomyocyte hypertrophy and fibrosis in
HFREF and HFREF patients [39]. The increased
MyD in HFREF was accompanied by collagen depo-
sition. In HFNEF, collagen deposition was associated
with a similar further increase in MyD. For each level
of CVF, MyD in HFNEF patients exceeded MyD in
HFREF patients. This excess cardiomyocyte hyper-
trophy in HFNEF was likely related to a history of ar-
terial hypertension, which was present in 73% of the
HFNEF patients and only 13% of the HFREF pa-
tients.
Cardiac hypertrophy has also been reported in ex-
perimental models of diabetes mellitus and insulin re-
sistance [18]. However, we previously noted Z-line
widening in humans as well as an associated elevation
in Fpassive [40]. Therefore, we suggested that Z-line
widening is associated with alterations in the elastic
properties of cytoskeletal proteins, which pull at and
open up adjacent Z lines.
Increased cardiomyocyte stiffness in HFNEF
The relative importance of Fpassive for LV myocardial
stiffness was also determined [6, 39]. LV endomyo-
cardial catheter biopsies (5 mg wet weight) procured
from control subjects and patients with HFNEF were
used for isolation of single cardiomyocytes. The rest-
ing tension (Fpassive – tension determined in Ca
2+-free
solution) of the cardiomyocytes was measured to de-
tect diastolic dysfunction at the level of cardiomyo-
cytes. When cardiomyocytes derived from HFNEF
patients were stretched to a sarcomere length of
2.2 m, Fpassive was found to be twice as high as that
of control cardiomyocytes [6] (Fig. 2). Treatment with
protein kinase A (PKA) induced a significant drop in
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Fig. 2. Cardiomyocyte stiffening in HFNEF.
(A) Representative force recording during
contraction-relaxation cycle obtained in a
single cardiomyocyte during maximal ac-
tivation (pCa 4.5). (B) Fpassive determined
in Ca2+-free solution (pCa 9) was signifi-
cantly higher in HFNEF than in control car-
diomyocytes. In vitro administration of
PKA (dotted line) reduced the elevated
Fpassive of HFNEF cardiomyocytes to the
level observed in the control group (the
difference between Ftotal and Fpassive is the
Ca2+-activated force, see text and ref. 6
for more details)
Fpassive in cardiomyocytes from HFNEF patients,
whereas Fpassive in control cardiomyocytes was unal-
tered [6]. In a follow-up study, Fpassive of HFREF car-
diomyocytes was found to be significantly lower than
that of HFNEF cardiomyocytes; however, PKA had
a similar effect on Fpassive of HFREF cardiomyocytes
[39].
Changes in the myofilamentary protein compo-
sition and phosphorylation
During isolation of cardiomyocytes, endomysial col-
lagen structures are removed; therefore, a high Fpassive
in cardiomyocytes of HFNEF patients can only result
from increased stiffness of the cardiomyocytes them-
selves. Because cardiomyocytes were also incubated
in solution supplemented with Triton X-100, the in-
tegrity of sarcolemmal and sarcoplasmic membranes
was disrupted. Under these conditions, disturbed cal-
cium handling (because of modified expression and/or
phosphorylation of sarcoplasmic reticular Ca2+-ATP-
ase [44], phospholamban [17, 28], sarcoplasmic cal-
cium release channels [29] and sodium/calcium ex-
changers [41]) was also ruled out as a possible cause
of the observed elevation in Fpassive. Therefore, the in-
creased cardiomyocyte stiffness must be attributed to
alterations of myofilament or cytoskeletal proteins.
However, no differences were found between the
HFNEF and control groups in the expression of car-
diac sarcomeric proteins, such as myosin heavy chain,
actin, TnT, TnI, desmin and tropomyosin [6]. More-
over, degradation of several contractile proteins, in-
cluding TnI, was ruled out in both the control and
HFNEF groups by western immunoblot analysis.
Therefore, it was unlikely that a change in isoform
composition or protein degradation accounted for the
high Fpassive of cardiomyocytes observed in the
HFNEF group. However, the high Fpassive could result
from hypophosphorylation of the sarcomeric target
proteins of PKA, which include TnI, myosin binding
protein-C, and/or titin. Consistent with this proposal,
PKA-mediated phosphorylation of the elastic N2B
spring element of titin was shown to reduce diastolic
stiffness in isolated rat cardiomyocytes [42]. How-
ever, the ratio of dephosphorylated to total TnI did not
differ between the cardiac tissues of patients from
the control and the HFNEF groups [6], so the fall in
Fpassive induced by in vitro PKA exposure likely re-
sulted from the correction of a phosphorylation deficit
of myosin binding protein-C or titin.
Future studies are clearly required to identify the
hypophosphorylated myofilamentary protein(s) re-
sponsible for the high cardiomyocyte Fpassive in
HFNEF. These hypophosphorylated sarcomeric pro-
teins, together with ECM modifications, could then be
considered myocardial targets for drug therapy of
HFNEF. Whether other protein kinases (PKC, PKD or
PKG) are also able to reduce cardiomyocyte Fpassive in
HFNEF cardiomyocytes or not also remains to be de-
termined.
Correlations between in vivo and in vitro
data
The transvascular catheter techniques have allowed
for assessment of in vivo hemodynamic characteris-
tics and for correlation with functional parameters
measured in vitro [6]. When Fpassive values of control
and HFNEF cardiomyocytes were pooled, significant
correlations were found between Fpassive and indices
of diastolic LV dysfunction, such as LVEDP, SM and
. The relations between Fpassive and indices of dia-
stolic LV function all leveled off at higher values of
LVEDP, , and E. This could result from diuretic ther-
apy to compensate patients before catheterization or
from more intense interstitial fibrosis at severe dia-
stolic LV dysfunction. Endomyocardial biopsy sam-
ples from patients with HFNEF had higher CVF than
did controls, and in a bivariate linear regression
analysis, both Fpassive and CVF were significantly cor-
related with LVEDP and . A predominant effect of
interstitial fibrosis upstream of diastolic LV dysfunc-
tion is consistent with previous experimental studies,
which showed diastolic muscle stiffness to originate
from structures within the sarcomere for sarcomere
lengths up to 2.2 m [26] and from perimysial fibers
once filling pressures exceeded 30 mmHg [14].
Conclusions
Because HFNEF patients can have subtle abnormali-
ties of systolic LV function and HFREF patients can
have diastolic LV dysfunction, the clinical classifica-
tion of heart failure patients into HFNEF and HFREF
Pharmacological Reports, 2009, 61, 139–145 143
Molecular determinants of HFNEF
Attila Borbély et al.
phenotypes is challenging. Recent basic studies com-
pared human LV myocardium of HFNEF and HFREF
patients and revealed significant differences at the
structural and functional levels. Moreover, in the ab-
sence of coronary artery disease, the mechanisms re-
sponsible for the elevated diastolic LV stiffness also
differed between diabetic HFREF and HFNEF pa-
tients. The distinct structural and functional abnor-
malities support HFNEF and HFREF as separate heart
failure phenotypes. These mechanistic basic studies
suggest that the reduction of high cardiomyocyte rest-
ing tension could serve as a potential therapeutic tar-
get for HFNEF patients.
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